- Home
- ATYR vs JELD Comparison
ATYR vs JELD Comparison
Compare ATYR & JELD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATYR
- JELD
- Stock Information
- Founded
- ATYR 2005
- JELD 1960
- Country
- ATYR United States
- JELD United States
- Employees
- ATYR N/A
- JELD N/A
- Industry
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- JELD Forest Products
- Sector
- ATYR Health Care
- JELD Basic Materials
- Exchange
- ATYR Nasdaq
- JELD Nasdaq
- Market Cap
- ATYR 306.2M
- JELD 326.7M
- IPO Year
- ATYR 2015
- JELD 2017
- Fundamental
- Price
- ATYR $5.15
- JELD $4.29
- Analyst Decision
- ATYR Strong Buy
- JELD Hold
- Analyst Count
- ATYR 6
- JELD 8
- Target Price
- ATYR $20.20
- JELD $7.34
- AVG Volume (30 Days)
- ATYR 3.4M
- JELD 1.5M
- Earning Date
- ATYR 08-12-2025
- JELD 08-04-2025
- Dividend Yield
- ATYR N/A
- JELD N/A
- EPS Growth
- ATYR N/A
- JELD N/A
- EPS
- ATYR N/A
- JELD N/A
- Revenue
- ATYR N/A
- JELD $3,592,472,000.00
- Revenue This Year
- ATYR $960.85
- JELD N/A
- Revenue Next Year
- ATYR $1,283.47
- JELD $3.40
- P/E Ratio
- ATYR N/A
- JELD N/A
- Revenue Growth
- ATYR N/A
- JELD N/A
- 52 Week Low
- ATYR $1.48
- JELD $3.27
- 52 Week High
- ATYR $5.98
- JELD $17.70
- Technical
- Relative Strength Index (RSI)
- ATYR 54.00
- JELD 50.56
- Support Level
- ATYR $4.78
- JELD $3.82
- Resistance Level
- ATYR $5.50
- JELD $4.00
- Average True Range (ATR)
- ATYR 0.36
- JELD 0.20
- MACD
- ATYR -0.09
- JELD 0.06
- Stochastic Oscillator
- ATYR 26.32
- JELD 70.00
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
About JELD JELD-WEN Holding Inc.
JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential single and multi-family homes and non-residential buildings. The firm's operating segments are North America, Europe, and Australasia. It generates a majority of its revenue from North America.